Originally published by our sister publication Gastroenterology & Endoscopy News
By Monica J. Smith
CHARLOTTE, N.C.—Patients with Crohn’s disease who progress from anti–tumor necrosis factor agents to one of two relatively new biologics tend to fair equally well in terms of persistence, regardless of whether they are treated with ustekinumab or vedolizumab, according to a new study.
“As we’ve heard a lot over the last decade, anti–[tumor necrosis factor